INDIA – Biocon Biologics, a Biocon subsidiary, has announced that it will purchase Viatris’ biosimilars business for US$3.3 billion in cash and stock. Viatris will receive US$2 billion in cash…
Read MoreBiocon to acquire Viatris’ biosimilars assets in a deal worth US$3.3 billion
